Welcome to our dedicated page for CBD LIFE SCIENCES news (Ticker: CBDL), a resource for investors and traders seeking the latest updates and insights on CBD LIFE SCIENCES stock.
CBD Life Sciences Inc. (CBDL) is a company focused on identifying, evaluating, and exploiting opportunities in the CBD space. Led by CEO Lisa Nelson, the company recently underwent a reverse split to rebrand its CBD products and launch a new product website. The rebranding is near completion, with an expected launch in mid-May 2024. CBDL aims to drive sales growth through wholesale and retail channel partnerships, with a full line of hemp-based organic products including CBD drops, pain relief creams, anxiety and sleep supplements, gummies, cartridges, and a pet line.
CBD Life Sciences (OTC PINK:CBDL) has announced a strategic partnership with Sunset Wholesale West, Arizona's largest wholesaler, through its subsidiary, LBC Bioscience Inc.. This alliance positions LBC to distribute its Elev8 gummies in large quantities, enhancing visibility across over 14,000 retailers, including dispensaries and smoke shops. CEO Lisa Nelson highlighted the potential for significant revenue growth and market expansion. The company aims to provide high-quality, affordable CBD products in 2023, continuing to address various health issues associated with CBD consumption.
CBD Life Sciences (CBDL) is launching a same day home delivery service for its CBD products across the Phoenix-Scottsdale Metro Area. This initiative, announced through its subsidiary LBC Bioscience Inc., aims to enhance convenience for local customers, especially the elderly. Orders can be placed via phone or online at www.lbcbioscienceinc.com. The company is also expanding its product offerings with a 2023 Mass Distributor Wholesale Catalog. All products are THC-free and undergo rigorous third-party lab testing. CBDL aims to improve customer accessibility and quality of life with its premium products.
CBD Life Sciences (OTC PINK: CBDL) announced the launch of a new CBD Oil infused with high-quality terpenes via its subsidiary, LBC Bioscience Inc.. The oil, available in strengths of 500MG, 1500MG, and 3000MG, will be sold online in 14 flavors. This product claims to have rapid absorption and is four times more potent than standard hemp-derived tinctures. The company has established a new manufacturing facility and anticipates increased revenue as it expands its product line. CBD's benefits extend to various health conditions, enhancing its market appeal.
CBD Life Sciences (OTC PINK: CBDL) has launched new Delta-8 gummies through its subsidiary, LBC Bioscience Inc.. Each gummy contains 100MG of Delta-8 THC, with a total of 2000MG per jar. The product employs a 2:1 blend of CBD and Delta-8, promoting a calming yet focused experience. The gummies will be available in-store and online shortly. The company emphasizes thorough testing for consistency and quality, supporting various health benefits associated with CBD, including pain management and neurological support.
CBD Life Sciences (OTC PINK:CBDL) announced a landmark event with the passage of the H.R. 8454 - Medical Marijuana and Cannabidiol Research Expansion Act, signed by both the U.S. House and Senate. This historic legislation creates a new framework for marijuana research, allowing registered entities to manufacture and distribute marijuana for medical purposes. CEO Lisa Nelson emphasized that this opens numerous opportunities as the perception of marijuana and CBD evolves. The bill aims to streamline research processes and remove barriers, promoting the benefits of CBD for various medical conditions.
CBD Life Sciences (OTC PINK:CBDL) announces the launch of its new product, PR-X 100MG tablets, designed to support prostate health, urinary, and hair needs. The product features natural ingredients combined with high-quality Full-Spectrum CBD Isolate, and has undergone lab testing for potency. CEO Lisa Nelson highlights this launch as a significant step for the company, aimed at driving revenue growth and expanding market reach in Arizona. The press release also notes the extensive benefits of CBD for various health conditions.
CBD Life Sciences (OTC PINK: CBDL) announces the launch of a Mobile CBD Store on Wheels, developed through its subsidiary, LBC Bioscience Inc.
This initiative aims to enhance revenue and growth by allowing the company to sell CBD products at various events across the U.S. The mobile store will offer popular items like pre-rolls, edibles, and CBD beverages. The food truck industry has seen an impressive growth rate of 12.1% annually, indicating strong potential for success in this venture. LBC Bioscience plans to keep shareholders updated on developments.
CBD Life Sciences (OTC PINK:CBDL) is set to launch a novel bladder control supplement via its subsidiary, LBC Bioscience Inc.. This all-natural product will be infused with CBD and aims to aid sleep, relieve stress, and control bladder function. The global cannabidiol market is projected to grow significantly from USD 3,675.1 million in 2022 to USD 55,791.3 million in 2028 at a CAGR of 47.49%. The company remains committed to keeping the public updated as research progresses on this innovative product.
CBD Life Sciences (OTC PINK: CBDL) has announced the launch of its new Green Apple Infused Gummies, featuring 15MG of Delta-8 and 10MG of Delta-9 per gummy. This product reflects the company's commitment to innovation and aims to enhance consumers' focus and mental well-being. Available in stores and soon on the LBC website, these gummies are rigorously tested for quality. The company, led by President & CEO Lisa Nelson, emphasizes its ongoing dedication to product development and shareholder updates through various online platforms.
CBD Life Sciences (OTC PINK:CBDL) announced the launch of its Delta-8 infused snacks through its subsidiary, LBC Bioscience Inc. The snacks come in five varieties, each containing 500MG of Delta-8. This legal cannabinoid is gaining popularity due to its mild psychoactive effects and potential therapeutic benefits. The company aims to maintain a competitive edge by using high-quality ingredients. The CBD market is projected to grow significantly, reaching USD 55.79 billion by 2028, indicating strong demand for cannabinoid products.
FAQ
What is the current stock price of CBD LIFE SCIENCES (CBDL)?
What is the market cap of CBD LIFE SCIENCES (CBDL)?
What is CBD Life Sciences Inc. focused on?
Who is the CEO of CBD Life Sciences Inc.?
What recent change did CBD Life Sciences Inc. undergo?
When is the expected launch of the rebranded products?
What products does CBD Life Sciences Inc. offer?
How does CBD Life Sciences Inc. plan to drive sales growth?
Where can shareholders and investors follow CBD Life Sciences Inc. for news and updates?
What is the Safe Harbor Statement of CBD Life Sciences Inc.?
How does CBD Life Sciences Inc. approach its ultimate objective of increasing shareholder value?